We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Detection of Anti-Leishmanial Antibodies in Patients' Sera

By LabMedica International staff writers
Posted on 21 Jan 2009
Diagnostic method using chemiluminescence and optical fiber immunosensor (OFIS) assays were evaluated for detecting anti-leishmanial antibodies in patients' sera. Leishmaniasis is a vector-borne disease caused by a flagellated protozoan parasite of the genus Leishmania, which affects both humans and animals.

Several serological tests are available for leishmaniasis including the indirect fluorescent antibody test (IFA), and enzyme-linked immunosorbant assay (ELISA), but each has limited sensitivity and specificity. Early infection with cutaneous leishmaniasis (CL) is associated with such a low level of antibody activity that it is sometimes undetectable.

Scientists from the Shraga Segal department of microbiology and immunology, the Ben Gurion University of the Negev (Beer Sheba, Israel) compared the efficacy of a chemiluminescence-enzyme-linked immunosorbant assay and an optical fiber immunosensor (OFIS) based on chemiluminesce, for the diagnosis of leishmaniasis, using highly sensitive and specific Leishmania antigens.

They found that the chemiluminescence-ELISA was 30 times more sensitive than the colorimetric-ELISA. The highest sensitivity (x60) was observed with the OFIS. However, high cross-reactivity was observed with sera from diseases such as malaria, toxocarosis, and strongyloidiasis patients. No cross- reactivity was demonstrated with sera from patients suffering from amoebiasis, toxoplasmosis, echinococosis, enterobiasis, and schistosomiasis.

The study suggested that the OFIS technique is very sensitive for the detection of anti-leishmanial antibodies in humans. Further studies using highly purified antigens are required to clarify the usefulness of the OFIS technique for diagnosis of the disease.

The study was presented by Lilach Eliyahu at the annual meeting of the Israel Society of Parasitology, Protozoology, and Tropical Medicine, which was held in Ramat Gan, Israel on December 17, 2008.

Related Links:

Ben Gurion University of the Negev




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
21 Jan 2009  |   Immunology

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
21 Jan 2009  |   Immunology

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
21 Jan 2009  |   Immunology